Pesquisar um ensaio clínico
Outras opções de pesquisa
47 Resultado(s)
Ensaio em fase de recrutamento = 
; Ensaio a decorrer = 
; Ensaio concluído = 
; Financiado por um membro do IRDiRC = 
; Membro de uma ERN = 
Ensaio (s) clínico (s) nacional (is)
ALEMANHA
Baden-Württemberg
ULM
RAS-ALS: Efficacy, Safety and Tolerability Study of 1 mg Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS) Receiving Standard Therapy (Riluzole) - An AMG Trial With a Market Authorized Substance (Phase II) - DE
Universitäts- und Rehabilitationskliniken Ulm (RKU)
Klinik für Neurologie
ALEMANHA
Baden-Württemberg
ULM
Pharyngeal Electrical Stimulation in Amyotrophic Lateral Sclerosis: A Pilot Study With 20 Patients (Phase I/II) DE
Universitäts- und Rehabilitationskliniken Ulm (RKU)
Klinik für Neurologie
ALEMANHA
Baden-Württemberg
ULM
TUDCA-ALS: Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS - DE-
Universitäts- und Rehabilitationskliniken Ulm (RKU)
Klinik für Neurologie
ALEMANHA
Baden-Württemberg
ULM
KETO-ALS: Efficacy and Tolerability of Beta Hydroxybutyrate in Patients With Amyotrophic Lateral Sclerosis (ALS)
Universitäts- und Rehabilitationskliniken Ulm (RKU)
Klinik für Neurologie
ALEMANHA
Bayern
MÜNCHEN
ROCK-ALS: Inhibition of Rho Kinase (ROCK) With Fasudil as Disease-modifying Treatment for ALS -DE-
Klinikum rechts der Isar der Technischen Universität München
Neurologische Klinik und Poliklinik
ALEMANHA
Berlin
BERLIN
ANA-ALS01: Open safety and tolerability phase II trial to evaluate a subcutaneous injection solution of 100 mg of Anakinra in combination with Riluzol in patients with Amyotrophic Lateral Sclerosis
Charité - Universitätsmedizin Berlin (CVK)
Klinik für Neurologie mit Experimenteller Neurologie (CVK)
AUSTRIA
TIROL
INNSBRUCK
REFALS: Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS (Amyotrophic Lateral Sclerosis) (Phase 3) - AT
Medizinische Universität Innsbruck
Universitätsklinik für Neurologie
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
REFALS-ES: Effects of oral Levosimendan (ODM-109) on respiratory function in patients with ALS (Amyotrophic Lateral Sclerosis): open label extension for patients completing study 3119002 (Phase 3) - AT
Institution: Information not provided - AT
CANADA
Québec
ADDRESS: NOT PROVIDED - CA
A Phase 3b, Multicenter, Randomized, Double-blind Extension Study to Evaluate the Continued Efficacy and Safety of Oral Edaravone Administered for an Additional Period of up to 48 Weeks Following Study MT-1186-A02 in Subjects With Amyotrophic Lateral Sclerosis (ALS) -CA
Institution: Information not provided - CA
ESPANHA
Andalucía
MÁLAGA
Placebo controlled, randomized and triple blind multicentric phase I/II clinical trial to evaluate the safety, feasibility and valoration of efficacy trends of intravenous administration of three doses of autologous adipose derived autologous mesenchymal stem cells (CeTMAd) in moderate/severe ALS patients - ES
Hospital Regional Universitario de Málaga - Hospital General
Unidad de Neurociencias
ESPANHA
Comunidad Valenciana
VALENCIA
ATLAS: A Phase 3 Randomized, Placebo-Controlled Trial With a Longitudinal Natural History Run-In and Open-Label Extension to Evaluate BIIB067 Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation - ES
Hospital Universitario y Politécnico La Fe
Servicio de Neurología
ESPANHA
Comunidad Valenciana
VALENCIA
IMCRELA: Impact of the combined treatment of the liposomated polyphenols curcula and resveratrol with dutasteride, in the clinical improvement of patients with ALS treated with riluzole - ES
Universidad Católica de Valencia San Vicente Mártir
Clínicas UCV
ESPANHA
Comunidad Valenciana
VALENCIA
Impact of the Combined Treatment of Curcumin and Resveratrol Liposomed Polyphenols With Dutasteride on the Clinical Improvement of ALS Patients - ES
Universidad Católica de Valencia San Vicente Mártir
Facultad de Enfermería
ESPANHA
Madrid
ADDRESS: NOT PROVIDED - ES
MERIDIAN: A Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of pegcetacoplan in subjects with amyotrophic lateral sclerosis (ALS) - ES
Institution: Information not provided - ES
ESPANHA
Madrid
ADDRESS: NOT PROVIDED - ES
An Extension Study to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB067 Administered to Previously Treated Adults with Amyotrophic Lateral Sclerosis Caused by Superoxide Dismutase 1 Mutation - ES
Institution: Information not provided - ES
ESPANHA
Madrid
ADDRESS: NOT PROVIDED - ES
COURAGE-ALS: A Phase 3, Multi-center, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Reldesemtiv in Patients with Amyotrophic Lateral Sclerosis (ALS) - ES
Institution: Information not provided - ES
ESPANHA
Madrid
ADDRESS: NOT PROVIDED - ES
Phoenix: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients with Amyotrophic Lateral Sclerosis (ALS) - ES
Institution: Information not provided - ES
ESPANHA
Madrid
ADDRESS: NOT PROVIDED - ES
A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with Riluzole versus placebo in combination with Riluzole in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS) - ES
Institution: Information not provided - ES
ESPANHA
Madrid
ADDRESS: NOT PROVIDED - ES
ADORE: A multicenter, randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of FAB122 in patients with Amyotrophic Lateral Sclerosis - ES
Institution: Information not provided - ES
ESPANHA
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase 2a Study of TPN-101 in Patients with C9ORF72 ALS/FTD (Amyotrophic Lateral Sclerosis and/or Frontotemporal Dementia) - ES
Institution: Information not provided - ES
ESPANHA
Murcia
EL PALMAR
TCIM-ELAII: Phase II clinical trial of intramuscular infusion of autologous bone marrow stem cells in patients with amyotrophic lateral sclerosis - ES
Hospital Clínico Universitario Virgen de la Arrixaca
Servicio de Hematología
ESTADOS UNIDOS
Kansas
KANSAS CITY
Phase 2 Study of Rasagiline for Treatment of Amyotrophic Lateral Sclerosis - US
University of Kansas Medical Center Research Institute
FRANCA
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
Study NOG112264, a Phase II Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis - FR
Institution: Information not provided - FR
FRANCA
HAUTS-DE-FRANCE
LILLE
FAIR-ALS II: Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis: Multicentre, Parallel-group, Placebo-controlled, Randomized Clinical Trial of Deferiprone
CHRU de Lille - Hôpital Roger Salengro
Service de Neurologie B
FRANCA
ILE-DE-FRANCE
PARIS
DOSERALS : Study of Dopamine and Serotonin Transporters in Patients With Amyotrophic Lateral Sclerosis and Controls. Analysis With 123I-FP-CIT (Datscan) and 123 I-ADAM Brain SPECT (Phase III) - FR
AP-HP.Sorbonne Université - Hôpital de la Pitié-Salpêtrière
Groupement hospitalier universitaire Pitié-Salpétrière
FRANCA
OCCITANIE
MONTPELLIER
MD1003-ALS : Effect of MD1003 in Amyotrophic Lateral Sclerosis: a Randomized Double Blind Placebo Controlled Pilot Study (Phase II)
CHU de Montpellier - Hôpital Gui de Chauliac
Clinique du Motoneurone et Pathologies neuromusculaires
FRANCA
OCCITANIE
MONTPELLIER
ROCK-ALS: Inhibition of Rho Kinase (ROCK) with Fasudil as disease-modifying treatment for ALS - FR
CHU de Montpellier - Hôpital Gui de Chauliac
Clinique du Motoneurone et Pathologies neuromusculaires
IRLANDA
County Dublin
DUBLIN
TUDCA-ALS: Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS - IE
Trinity College Dublin
Research Motor Neurone - Trinity Biomedical Sciences Institute
ITALIA
CAMPANIA
NAPOLI
Efficacy safety and tolerability of growth hormone in patients with amyotrophic lateral sclerosis as add-on therapy to Riluzole-Phase II
Azienda Ospedaliera Universitaria "Federico II"
AOU Federico II
ITALIA
LAZIO
ROMA
Efficacy of Transcranial Static Magnetic Field Stimulation (tSMS) in Amyotrophic Lateral Sclerosis (ALS)
Policlinico Universitario Campus Bio-Medico
U.O.C. Neurologia
ITALIA
LOMBARDIA
BRESCIA
Cortico-Spinal tDCS as Rehabilitative Intervention in Amyotrophic Lateral: a Randomized, Double-blind, Sham-controlled Trial Followed by an Open-label Phase
ASST Spedali Civili di Brescia
II Divisione di Neurologia
ITALIA
LOMBARDIA
MILANO
Tolerability, Safety and Efficacy of Sigh During Non-invasive Mechanical Ventilation in Patients With Motor Neuron Disease - A Pilot Study
IRCCS Ospedale San Raffaele
U.O. di Neurologia
PAISES BAIXOS
Utrecht
UTRECHT
Targeting Metabolic Flexibility in ALS (MetFlex); Safety and Tolerability of Trimetazidine for the Treatment of ALS - NL
UMC Utrecht - Universitair Medisch Centrum Utrecht
Polikliniek Neuromusculaire Ziekten
POLONIA
Szczecin
SZCZECIN
Safety/Efficacy Study for the Biological Treatment of Amyotrophic Lateral Sclerosis With Autologous Stem/Progenitor Cells
Zaklad Patologii Ogolnej
REINO UNIDO
West Midlands
BIRMINGHAM
A Phase II Pilot Single-arm Safety and Tolerability Study of ILB in Patients With Motor Neurone Disease (MND)/ Amyotrophic Lateral Sclerosis (ALS) -GB
University of Birmingham
Institute for cancer studies
SUECIA
Region Stockholm
STOCKHOLM
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Amyotrophic Lateral Sclerosis - SE
Karolinska Institutet - Solna
Department of Clinical Neuroscience (CNS)
SUICA
Suisse Alémanique
ST. GALLEN
ROCK-ALS : Inhibition of Rho Kinase (ROCK) with Fasudil as disease-modifying treatment for ALS - CH
Kantonsspital St. Gallen
Muskelzentrum/ ALS clinic
Ensaio (s) clínico (s) multinacional (ais)
ALEMANHA
Bayern
MÜNCHEN
ROCK-ALS: Inhibition of Rho Kinase (ROCK) with Fasudil as disease-modifying treatment for ALS
Klinikum rechts der Isar der Technischen Universität München
Neurologische Klinik und Poliklinik
AUSTRALIA
Queensland
QUEENSLAND
Targeting Metabolic Flexibility in ALS (MetFlex); Safety and Tolerability of Trimetazidine for the Treatment of ALS
Royal Brisbane & Women's Hospital
ESTADOS UNIDOS
California
SOUTH SAN FRANCISCO
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerability and Efficacy of Tirasemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
A Phase 1, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB067 Administered to Adult Subjects With Amyotrophic Lateral Sclerosis
Institution: Information not provided - US
ESTADOS UNIDOS
Washington
ADDRESS: NOT PROVIDED - US
A Phase 3b, Multicenter, Randomized, Double-blind Extension Study to Evaluate the Continued Efficacy and Safety of Oral Edaravone Administered for an Additional Period of up to 48 Weeks Following Study MT-1186-A02 in Subjects With Amyotrophic Lateral Sclerosis (ALS).
Institution: Information not provided - US
FINLANDIA
Finland
ESPOO
FINLANDIA
Finland
ESPOO
FINLANDIA
Finland
ESPOO
REFALS: Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS (Amyotrophic Lateral Sclerosis)
Orion Corporation
FRANCA
PROVENCE-ALPES-COTE D'AZUR
MARSEILLE